Back in the Q1 2016 Corporate Update, Don mentioned that Taiwan would be included in BETonMACE and should launch soon. And if I remember correctly from past updates, it was anticipated that there would be ~150 patients from China in BETonMACE and paid for by Hepalink. Since BETonMACE is still in the recruiting stage, I don't think there's any reason to believe that those plans have changed.

You make a good point about us not knowing about the status of other potential trials in China as part of the Hepalink/RVX208 licensing deal. However, they are likely only licensed for pursuing certain indications that are already being studied in BETonMACE or BETONRENAL. So most likely not much further action from the licensing deal until those trials wrap up.

In other news, today marks 8 months since initial dosing in BETonMACE!

BearDownAZ